0001104659-24-063598.txt : 20240521 0001104659-24-063598.hdr.sgml : 20240521 20240521060235 ACCESSION NUMBER: 0001104659-24-063598 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240520 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Astrana Health, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 24966750 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: Apollo Medical Holdings, Inc. DATE OF NAME CHANGE: 20080715 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm2414976d1_8k.htm FORM 8-K
false 0001083446 0001083446 2024-05-20 2024-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 20, 2024

 

ASTRANA HEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware 001-37392 95-4472349
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

 

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

 

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ASTH The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

 

 

   

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On May 20, 2024, Astrana Health, Inc. (the “Company”) entered into a Fourth Amendment to Amended and Restated Credit Agreement (the “Credit Agreement Amendment”) with the banks and other financial institutions party thereto and Truist Bank, as administrative agent, which amends the Amended and Restated Credit Agreement, dated as of June 16, 2021, entered into among the Company, the lenders party thereto and Truist Bank, as administrative agent (as amended, the “Credit Agreement”). The Credit Agreement Amendment updates the letter of credit provisions in the Credit Agreement to provide the Company with the ability to have letters of credit issued under the Credit Agreement that extend beyond the maturity date of the Credit Agreement.

 

The above description of the Credit Agreement Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Credit Agreement Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this item.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
10.1   Fourth Amendment to Amended and Restated Credit Agreement, dated as of May 20, 2024, by and among Astrana Health, Inc., as borrower, Astrana Health Management, Inc., as guarantor, the lenders party thereto, and Truist Bank, as administrative agent, issuing bank and the swingline lender.
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASTRANA HEALTH, INC.
   
Date: May 21, 2024 By:  /s/ Brandon Sim
  Name:  Brandon Sim
  Title:  Chief Executive Officer and President

 

 

 

 EX-10.1 2 tm2414976d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT

 

THIS FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of May 20, 2024 (this “Amendment”), is made by and among ASTRANA HEALTH, INC. (f/k/a Apollo Medical Holdings, Inc.), a Delaware corporation (the “Borrower”), ASTRANA HEALTH MANAGEMENT, INC. (f/k/a Network Medical Management, Inc.), a California corporation (the “Guarantor”), each of the banks and other financial institutions signatory hereto as “Lenders” and TRUIST BANK, in its capacity as Administrative Agent (in such capacity, the “Administrative Agent”) for the Lenders, as Issuing Bank and as the Swingline Lender.

 

W I T N E S S E T H:

 

WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to that certain Amended and Restated Credit Agreement dated as of June 16, 2021 (as amended by that certain First Amendment to Amended and Restated Credit Agreement dated as of December 20, 2022, that certain Second Amendment to Amended and Restated Credit Agreement and Waiver dated as of September 8, 2023, that certain Third Amendment to Amended and Restated Credit Agreement and Incremental Agreement dated as of November 3, 2023 and as otherwise amended, restated, supplemented or modified from time to time prior to the date hereof, the “Existing Credit Agreement”);

 

WHEREAS, the Administrative Agent, the Issuing Bank and the Lenders have been made aware that the Borrower has requested that the Issuing Bank issue certain Letters of Credit with expiration dates after the Revolving Commitment Termination Date (“Post-Maturity LCs”);

 

WHEREAS, in connection with the foregoing, the Borrower has requested that the Administrative Agent, the Issuing Bank and the Required Lenders amend certain provisions of the Existing Credit Agreement to permit the issuance of Post-Maturity LCs; and

 

WHEREAS, subject to the terms and conditions set forth herein, the Administrative Agent, the Issuing Bank and the Required Lenders are willing to amend the Existing Credit Agreement to permit the issuance of Post-Maturity LCs as set forth herein.

 

NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties hereto hereby agree as follows:

 

Section 1. Defined Terms. Except as otherwise defined herein, capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Existing Credit Agreement, as amended by this Amendment (the “Amended Credit Agreement”).

 

Section 2. Amendments to Existing Credit Agreement. The Loan Parties, the Administrative Agent, the Issuing Bank and the Lenders signatory hereto (which, for the avoidance of doubt, constitute “Required Lenders”) hereby agree to the following amendments:

 

(a)           Section 1.1 of the Existing Credit Agreement is hereby amended to add the following defined term in the appropriate alphabetical order:

 

“Post-Maturity LC” shall mean any Letter of Credit that has an expiration date that is after the date set forth in clause (i) of the definition of “Revolving Commitment Termination Date”.

 

(b)           Section 2.22(a) of the Existing Credit Agreement is hereby amended by amending and restating clause (i) of the proviso in its entirety as follows:

 

“(i) each Letter of Credit shall expire on the earlier of the date that is two (2) years after the date of issuance of such Letter of Credit (or, in the case of any renewal or extension thereof, two (2) years after such renewal or extension);”

 

 

(c)           Section 2.22 of the Existing Credit Agreement is hereby further amended by inserting the following new clause (m) at the end of such Section:

 

“(m)         With respect to each Post-Maturity LC (if any), the Borrower shall deposit, on or before the date that is five (5) Business Days prior to the date set forth in clause (i) of the definition of “Revolving Commitment Termination Date”, in an account with the Administrative Agent, in the name of the Administrative Agent and for the benefit of the Issuing Banks (as applicable) and the Revolving Lenders, an amount in cash equal to the greater of (x) 105% of the sum of (i) the aggregate undrawn amount of all outstanding Post-Maturity LCs at such time, plus (ii) the aggregate amount of all LC Disbursements in respect of Post-Maturity LCs that have not been reimbursed by or on behalf of the Borrower at such time plus (iii) any accrued and unpaid fees in respect of the Post-Maturity LCs and (y) an amount determined by the Administrative Agent and the Issuing Bank in their reasonable discretion (with the Administrative Agent and the Issuing Bank providing Borrower reasonable evidence supporting the calculation and determination of such additional amount) to collateralize the remaining exposure (including margin, fees, etc.) in respect the Post-Maturity LCs through their expiration (the “Post-Maturity LC Exposure”). The Administrative Agent shall have exclusive dominion and control, including the exclusive right of withdrawal, over such account, until the earlier of the date of payment in full and the Revolving Commitment Termination Date, at which time the amount on deposit in such account shall be transferred to each applicable Issuing Bank for cash collateral in respect of Post-Maturity LCs that remain outstanding. Moneys in such account shall be applied by the Administrative Agent, prior to the earlier of the date of payment in full and the Revolving Commitment Termination Date, to reimburse each Issuing Bank for LC Disbursements for which it had not been reimbursed. On or before the Revolving Commitment Termination Date, the Borrower and each applicable Issuing Bank shall execute a customary “cash collateral agreement” in order to cause the cash collateral to be held by such Issuing Bank to be applied in satisfaction of all obligations of the Borrower for the Post-Maturity LC Exposure; provided that upon the undrawn expiration of each Post-Maturity LC, the applicable Issuing Bank shall return any remaining cash collateral (after payment of fees and expenses) in respect of such Post-Maturity LC to the Borrower within three (3) Business Days after the Borrower’s written request therefor. Notwithstanding anything to the contrary contained in the Loan Documents, in the case of any cash collateralization of Post-Maturity LCs in the context of the payment in full (due to a refinancing or otherwise) or acceleration, the amount to be cash collateralized for such Post-Maturity LCs shall be determined as set forth in clauses (x) and (y) above.”

 

Section 3. Conditions Precedent to Effectiveness. This Amendment shall become effective as of the date on which each of the following conditions precedent are satisfied:

 

(a)           the Administrative Agent (or its counsel) shall have received a counterpart of this Amendment duly executed by each of the Borrower, the Guarantor, the Administrative Agent, the Issuing Bank and the Required Lenders; and

 

(b)           the representations and warranties in Sections 4 and 5 hereof shall be true and correct in all material respects on and as of the date hereof (other than those representations and warranties that are expressly qualified by a Material Adverse Effect or other materiality, in which case such representations and warranties shall be true and correct in all respects).

 

The Loan Parties, the Lenders, the Issuing Bank and the Administrative Agent hereby acknowledge and agree that as of the date hereof, the conditions precedent to effectiveness as set forth in this Section 3 have been satisfied and this Amendment is effective as of the date hereof.

 

2

 

Section 4. Representations. The Loan Parties represent and warrant to the Administrative Agent, the Issuing Bank and the Lenders that:

 

(a)           Power and Authority. Each of the Loan Parties has the power and authority to execute, deliver and perform the terms and provisions of this Amendment and the Amended Credit Agreement, and have taken all necessary corporate or equivalent action to duly authorize the execution, delivery and performance of this Amendment. This Amendment has been duly executed and delivered by each Loan Party. Each of this Amendment and the Amended Credit Agreement constitutes the legal, valid and binding obligation of the Borrower or the Guarantor (as the case may be) enforceable in accordance with its terms, except to the extent that the enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights and by equitable principles.

 

(b)           No Violation. The execution, delivery and performance by the other Loan Parties of this Amendment, and compliance by them with the terms and provisions of the Amended Credit Agreement: (i) will not violate any Requirement of Law or any judgment, order or ruling of any Governmental Authority, (ii) will not violate or result in a default under any Contractual Obligation of the Borrower or any of its Subsidiaries or any of its assets or give rise to a right thereunder to require any payment to be made by the Borrower or any of its Subsidiaries, or (iii) will not result in the creation or imposition of any Lien on any asset of any Loan Party except Liens created under the Loan Documents.

 

(c)           Governmental Approvals. No order, consent, approval, license, authorization or validation of, or filing, recording or registration with (except for those that (x) have otherwise been obtained or made on or prior to the date of the effectiveness of this Amendment and which remain in full force and effect on such date and (y) the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect), or exemption by, any Governmental Authority, is required to authorize, or is required in connection with, (i) the execution, delivery and performance of this Amendment by the Loan Parties or (ii) the legality, validity, binding effect or enforceability of the Amended Credit Agreement.

 

(d)           No Default. No Default or Event of Default has occurred and is continuing as of the date hereof and no Default or Event of Default will exist immediately after giving effect to this Amendment.

 

Section 5.          Reaffirmation of Representations. The Borrower and the other Loan Parties hereby repeat and reaffirm in all material respects all representations and warranties made to the Administrative Agent, the Issuing Bank and the Lenders in the Existing Credit Agreement and the other Loan Documents on and as of the date hereof (and after giving effect to this Amendment) with the same force and effect as if such representations and warranties were set forth in this Amendment in full (except to the extent that such representations and warranties relate expressly to an earlier date, in which case such representations and warranties were true and correct in all material respects as of such earlier date).

 

Section 6.          No Further Amendments; Ratification of Liability. Except as expressly amended hereby, the Existing Credit Agreement and each of the other Loan Documents, as amended hereby, shall remain in full force and effect in accordance with their respective terms, and the Lenders, the Issuing Bank and the Administrative Agent hereby require strict compliance with the terms and conditions of the Amended Credit Agreement and the other Loan Documents, as amended hereby, in the future. No Loan Party has any knowledge of any challenge to the Administrative Agent’s or any Lender’s claims arising under the Loan Documents. Each of the Borrower and the other Loan Parties hereby (i) ratifies, confirms and reaffirms its respective liabilities, payment and performance obligations (contingent or otherwise) and each and every term, covenant and condition set forth in the Amended Credit Agreement and the other Loan Documents to which it is a party, all as amended by this Amendment and (ii) acknowledges and agrees that this Amendment shall not in any way affect the validity and enforceability of any Loan Document, as amended hereby, to which it is a party, or reduce, impair or discharge the obligations of the Borrower or any other Loan Party. The Guarantor hereby acknowledges its receipt of a copy of this Amendment and its review of the terms and conditions hereof and consents to the terms and conditions of this Amendment and the transactions contemplated hereby. The Guarantor hereby (a) affirms and confirms its guarantees under the Guaranty and Security Agreement, and (b) agrees that (i) Guaranty and Security Agreement shall continue to be in full force and effect and (ii) all guarantees under the Guaranty and Security Agreement shall continue to be in full force and effect and shall accrue to the benefit of the Lenders. The Lenders’ agreement to the terms of this Amendment or any other amendment of the Existing Credit Agreement or any other Loan Document shall not be deemed to establish or create a custom or course of dealing between the Borrower or any other Loan Party or the Lenders, or any of them. This Amendment shall be deemed to be a “Loan Document” for all purposes under the Amended Credit Agreement. After the effectiveness of this Amendment, each reference to the Existing Credit Agreement in any of the Loan Documents shall be deemed to be a reference to the Amended Credit Agreement.

 

3

 

Section 7.          Miscellaneous. Sections 10.5 (Governing Law; Jurisdiction; Consent to Service of Process), 10.6 (Waiver of Jury Trial), 10.8 (Counterparts; Integration), 10.10 (Severability) and 10.21 (Electronic Signatures), of the Amended Credit Agreement are hereby incorporated by reference into this Amendment and shall apply hereto mutatis mutandis.

 

[Signature Pages Follow]

 

4

 

IN WITNESS WHEREOF, the Borrower, the Guarantor, the Lenders and the Administrative Agent have caused this Fourth Amendment to Amended and Restated Credit Agreement to be duly executed by their respective duly authorized officers and representatives as of the day and year first above written.

 

  bORROWER:
   
  ASTRANA HEALTH, INC.
   
   
  By: /s/ Brandon Sim
  Name: Brandon Sim
  Title: President and Chief Executive Officer
     
  By: /s/ Chandan Basho
  Name: Chandan Basho
  Title: Chief Financial Officer, Chief Operating Officer and Corporate Secretary
     
     
  GUARANTOR:
   
  ASTRANA HEALTH MANAGEMENT, INC.
   
   
  By: /s/ Thomas S. Lam, M.D., M.P.H.
  Name: Thomas S. Lam, M.D., M.P.H.
  Title:

Chief Executive Officer

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  TRUIST BANK, as Administrative Agent, as the Issuing Bank, as the Swingline Lender and as a Lender
   
   
  By: /s/ Anton Brykalin     
  Name: Anton Brykalin
  Title: Director

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  JPMORGAN CHASE BANK, N.A., as a Lender
   
   
  By: /s/ Ling Li
  Name: Ling Li
  Title:

Executive Director

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  PREFERRED BANK, as a Lender
   
   
  By: /s/ Samuel Leung
  Name:

Samuel Leung

  Title: Senior Vice President

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  FIFTH THIRD BANK, NATIONAL ASSOCIATION, as a Lender
   
   
  By: /s/ Thomas Avery
  Name: Thomas Avery
  Title: Managing Director

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  ROYAL BANK OF CANADA, as a Lender
   
   
  By: /s/ Sean Young
  Name: Sean Young
  Title: Authorized Signatory

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  THE TORONTO DOMINION BANK, NEW YORK BRANCH, as a Lender
   
   
  By: /s/ Mike Tkach
  Name: Mike Tkach
  Title: Authorized Signatory

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender
   
   
  By: /s/ Yinghua Zhang         
  Name: Yinghua Zhang
  Title: Senior Vice President

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

  CITY NATIONAL BANK, as a Lender
   
   
  By: /s/ Eric Rezai  
  Name: Eric Rezai
  Title: Vice President

 

ASTRANA HEALTH, INC.

FOURTH AMENDMENT TO A&R CREDIT AGREEMENT

SIGNATURE PAGE

 

 

 

 

 

 

 EX-101.SCH 3 ameh-20240520.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ameh-20240520_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ameh-20240520_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 20, 2024
Entity File Number 001-37392
Entity Registrant Name ASTRANA HEALTH, INC.
Entity Central Index Key 0001083446
Entity Tax Identification Number 95-4472349
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1668 S. Garfield Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Alhambra
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91801
City Area Code 626
Local Phone Number 282-0288
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ASTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports ameh-20240520.xsd ameh-20240520_lab.xml ameh-20240520_pre.xml tm2414976d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414976d1_8k.htm": { "nsprefix": "AMEH", "nsuri": "http://apollomed.net/20240520", "dts": { "schema": { "local": [ "ameh-20240520.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ameh-20240520_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20240520_pre.xml" ] }, "inline": { "local": [ "tm2414976d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://apollomed.net/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414976d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414976d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-063598-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-063598-xbrl.zip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tm2414976d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2024-05-20 2024-05-20 iso4217:USD shares iso4217:USD shares false 0001083446 8-K 2024-05-20 ASTRANA HEALTH, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock ASTH NASDAQ false